淄博百极常生制药

Zibo Baiji Changsheng Pharmaceutical Co., Ltd. is a clinical-stage biopharmaceutical company based in Zibo, Shandong Province, China. Founded in April 2017, the company was established through a collaboration involving local government initiatives, private capital, and a scientific team from the Shanghai Institute of Materia Medica under the Chinese Academy of Sciences. Zibo Baiji Changsheng focuses on the discovery and development of innovative small molecule therapeutics for oncology, hematology, and immunological disorders. Its lead clinical candidate is SS-001, a novel Bruton's tyrosine kinase (BTK) inhibitor currently undergoing Phase 1 clinical trials in China for the treatment of relapsed or refractory B-cell lymphoma.